Popular Articles

Emergency Prescribing - A Change For Dentists
The General Dental Council (GDC) is welcoming a change in the law that regulates who can and who can"t request an emergency supply of a prescription-only medicine in the UK.

UNDP To Help Fund HIV/AIDS Program In Philippines
The U.N. Development Program (UNDP) will help fund a three-year program in response to the increase in HIV/AIDS cases in the Philippines, the Manila Bulletin reports. The program aims to help the country combat the spread of the disease and reach the related U.N. Millennium Development Goal (MDG) targets. "The program has five components that aim to develop intervention packages, especially among vulnerable and at-risk groups in rural areas," writes the Manila Bulletin (Sabater, 7/23).
News of the day
PPD Confirms Takeda Receives FDA Complete Response For Alogliptin
PPD, Inc. (NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.
Mental Health

Roche Launches Complete Detection Kit For Influenza A /H1N1 On LightCycler(R) System

Roche Applied Science announced the availability of a new detection kit for the Influenza A/H1N1 virus. The detection kit is offered for use in life science research. Roche currently is filing to get approval of the local health authorities worldwide for use of the kit in emergency situations. The kit runs on Roche÷´s LightCycler® 480 II, 2.0, and 1.5 systems. It was evaluated with virus positive sample materials and selectively identifies the new Influenza A H1N1 virus. Compared with other detection kits, it features a couple of advantages in regard to efficiency and handling. "The design of the new detection kits benefitted very much from information we got out of our manifold research cooperations. We are glad of our contribution in supplying fast and reliable tools for the detection of Influenza A/H1N1 to the research community," said Manfred Baier, Head of Roche Applied Science. Applied Science offers a variety of platforms that can be used to help identify the Influenza A H1N1 virus, including Nucleic Acid Purification, Real-Time PCR, Microarrays and Sequencing systems. The company is in close contact with various research institutions and test centers worldwide providing assistance in the detection and characterization of Influenza A H1N1 virus. Currently, there is no human vaccine on the market that protects against Influenza A H1N1 infection. Standard therapy for the disease includes treatment with antiviral drugs like Tamiflu or Relenza. For more information on Influenza A H1N1 please visit www.who.int. Roche


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):